Prolonged peripheral seronegative spondyloarthritis following BioNTech coronavirus disease 2019 vaccination: A case report

A female 17‐year‐old diagnosed with seronegative spondyloarthritis (SpA) following the first jab of the BioNTech162b2 (BNT162b2) vaccine presented with recurrent swelling and painful knee accompanied by posterior heel tenderness over the past 1.5 months. Laboratory investigations revealed elevated s...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of rheumatic diseases Vol. 26; no. 4; pp. 774 - 777
Main Authors Koh, Shu‐Yi, Chen, Hui‐Ming, Hsu, Chung‐Yuan
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.04.2023
Subjects
Adolescent
Arthritis
Autoimmune diseases
Autoimmunity
BNT162 Vaccine
Case reports
Celecoxib
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - prevention & control
COVID‐19 vaccination
Effusion
Erythrocyte sedimentation rate
Etanercept
Female
Histocompatibility antigen HLA
Humans
Inflammation
Inflammatory diseases
Methylprednisolone
mRNA
Rheumatic diseases
Seronegative spondyloarthritis
Spondylarthritis - complications
Spondylarthritis - diagnosis
Spondylarthritis - drug therapy
Sulfasalazine
Vaccination
COVID-19 vaccination
Seronegative spondyloarthritis
Online AccessGet full text

Cover

More Information
Summary:A female 17‐year‐old diagnosed with seronegative spondyloarthritis (SpA) following the first jab of the BioNTech162b2 (BNT162b2) vaccine presented with recurrent swelling and painful knee accompanied by posterior heel tenderness over the past 1.5 months. Laboratory investigations revealed elevated serum erythrocyte sedimentation rate and C‐reactive protein. Synovial aspiration yielded level 3 crystal‐free, aseptic and inflammatory effusion. She tested positive for the human leukocyte antigen‐B27 and was diagnosed with peripheral SpA. She received daily celecoxib (400 mg), methylprednisolone (8 mg), and sulfasalazine (2 g), but the effect was limited. Nonetheless, her symptoms improved significantly with weekly subcutaneous etanercept administration (50 mg). Four weeks later, her arthritis was completely resolved. To our knowledge, this is the first case report of newly diagnosed seronegative peripheral SpA in an autoimmunity‐disease‐free individual following messenger RNA BNT coronavirus disease 2019 vaccination.
ISSN:1756-1841
1756-185X
DOI:10.1111/1756-185X.14512